ASX healthcare stocks wrapped up October with a real spring in their step. The S&P/ASX 200 Health Care index (ASX:XHJ) rose 1.66% over five days. The broader S&P/ASX 200 (ASX:XJO) did slightly better, up 1.91%.
Not everyone is popping champagne, though. Scott Power has spent 29 years as a senior analyst at Morgans Financial, and he sees a cautious market. Interest rates are largely tipped to rise again on Melbourne Cup day. Higher-than-expected inflation data this week added fuel to that view.
So what is really going on? This article covers the what, why, where, when and how. You will see which Australian healthcare stocks are moving and the numbers behind each call. It also flags the risks. That way, you can weigh the best ASX healthcare stocks with open eyes.
Why ASX Healthcare Stocks Are Rising
Money is rotating into the sector, and that is the short answer. Power says a global cycle of rising rates is hurting growth stocks. He calls it a risk-off market right now. Investors appear to be seeking steadier ground, and healthcare is catching the flow.
Seasonality should help too. The last couple of months of the year are typically stronger. Even so, Power says the market mood is not offering much encouragement. That explains why the gains feel solid but careful. Analysts at Morgans are leaning on proven earnings rather than hype.
Year-end seasonality may help, but rate risks still weigh on sentiment. [The Economic Times]
What Is Happening at CSL?
CSL (ASX:CSL) is the sector’s biggest stock, so its news moves the whole board. Here is the rundown:
- CSL named Deborah Waterhouse as CEO and managing director, effective February 1, 2027.
- Waterhouse brings three decades of experience from pharmaceutical giant GSK.
- Gordon Naylor, interim CEO since February, will succeed Brian McNamee as chairman.
- McNamee led CSL from 1990 to 2013 and retired on March 31, 2027.
- Carolyn Hewson becomes senior independent director from March 31, 2027.
- FY27 guidance was reaffirmed, with revenue in line with the previous year.
- Underlying net profit after tax is forecast to grow about 5%, against consensus of ~4.5%.
- The share price has climbed ~57% in the past six months.
- Morgans keeps a buy rating and a 12-month target of $187.71.
Analyst Dr Derek Jellinek called the AGM reassuring. Management said Behring and Seqirus are performing to expectations. He believes the downgrade cycle is behind the company. Still, he would not chase the shares after such a big run. Further upside, he says, needs real earnings delivery and not just better sentiment.
Best ASX Healthcare Stocks: Cochlear in Focus
Where does Cochlear (ASX:COH) sit among the best ASX healthcare stocks? Mostly in the hold camp, for now. The hearing giant reaffirmed its FY27 guidance at its AGM. It gave no trading update. The key numbers are below:
- COH targets FY27 NPAT of $330-350 million, representing growth of 2-9%.
- Consensus sits near the midpoint at $339m, while Morgans estimates $336m.
- FY26 sales reached $2.3 billion, up 2% in constant currency terms.
- FY26 NPAT fell 21% to $322m as slower developed markets weighed.
- The Nucleus Nexa System launched as the world’s first smart cochlear implant system.
- Morgans has a hold rating and a 12-month price target of $138.42.
CEO Dig Howitt told shareholders the strategy remains sound. He says fixed costs have fallen as a share of revenue. Jellinek sees a high-quality business with strong structural growth potential. However, he does not expect Nexa to be a step-change catalyst. Earnings should recover gradually rather than sharply.
How Are the Small Caps Performing?
Smaller Australian healthcare stocks gave a more mixed picture. Many of them depend on US regulators and US customers. Here is how each one stacks up:
- Echo IQ (ASX:EIQ): It logged 9697 full-result EchoSolv AS assessments in the September quarter, up 193% year-on-year. The FDA declined to clear EchoSolv HF, and the company is appealing. Analyst Iain Wilkie rates a supervisory appeal success as low probability. Morgans has a speculative buy rating and a $1.10 target.
- Mach7 Technologies (ASX:M7T): It posted a fourth consecutive quarter of positive operating cash flow, at $300,000 in Q1 FY27. ARR run rate grew 8.5% to $23.5m, while CARR fell 7.4%. R&D spending is rising 150%. Morgans has a buy rating and a 48 cent target.
- Tetratherix (ASX:TTX): It shipped its first commercial Tetramatrix polymer to the US. The company finished the quarter with $26.4m in cash and no debt. A new campus should lift capacity ~15-fold. Morgans has a speculative buy rating and an $8.59 target.
When Could the Rally Fade?
Risks sit close at hand. A rate rise on Melbourne Cup day could pressure growth names again. CSL has rallied hard, so any earnings stumble may sting. Cochlear still needs to prove that its recovery is real.
The small caps carry their own calendar. Mach7 heads to the RSNA annual meeting later this year. Wilkie wants to see whether early Flamingo traction turns into contract wins. Its shares are down ~60% year-to-date, though they bounced ~14% last week. Tetratherix is awaiting an FDA decision on its dental 510(k) submission. Timing there remains hard to predict.
How should investors approach all this? Watch cash positions, guidance and regulatory updates. Companies with clear earnings delivery may cope better if rates keep climbing.
Also Read: Why SGQ Looks Undervalued After Lynas’ A$968m Meteoric Deal
FAQs
Q1: What are the best ASX healthcare stocks right now?
A1: Morgan’s rates CSL and Mach7 a buy, while Cochlear is a hold. Echo IQ and Tetratherix hold speculative buy ratings.
Q2: Why are ASX healthcare stocks rising?
A2: Investors are rotating into the sector during a risk-off market. The health index gained 1.66% over five days.
Q3: When does CSL’s new CEO start?
A3: Deborah Waterhouse took over on February 1, 2027. Chairman Brian McNamee retires on March 31, 2027.
Q4: How did Cochlear perform in FY26?
A4: Sales reached $2.3 billion, up 2% in constant currency terms. NPAT fell 21% to $322m.
Disclaimer:
This article should be treated as general information and not financial advice. All opinions and targets stated are of Morgans and not ours. Investing in the listed speculative small caps like Echo IQ, Mach7 and Tetratherix may result in significant volatility. In addition to potential volatility due to macro and interest rate decisions, you should conduct your own analysis before investing and take your personal financial goals and risk tolerance into account with a licensed advisor.
Luke Carlino is a seasoned Copywriter, Content Strategist, and Social Media Manager specialising in Mining, Finance, and Business journalism. With more than a decade of industry experience, he brings rigorous editorial standards and commercial acuity to every project.
